内皮素受体拮抗剂在 IgA 肾病中的作用。

IF 2.4 4区医学 Q2 UROLOGY & NEPHROLOGY

Nephrology Pub Date : 2024-09-01 DOI:10.1111/nep.14364

Mitchell Hunter-Dickson, Muh Geot Wong

{"title":"内皮素受体拮抗剂在 IgA 肾病中的作用。","authors":"Mitchell Hunter-Dickson, Muh Geot Wong","doi":"10.1111/nep.14364","DOIUrl":null,"url":null,"abstract":"There is growing evidence of endothelin receptor antagonists (ERAs) in renoprotection in proteinuric kidney disease including IgA nephropathy (IgAN). Here, we review current evidence, including the use of sparsentan, atrasentan and zibotentan in IgAN. Recent trails of combination therapy including SGLT2 inhibitors and ERAs suggest possible benefit in further reduction of proteinuria and reducing ERA fluid-retention side effects although more evidence is needed for clinical applications.","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 2 ","pages":"30-33"},"PeriodicalIF":2.4000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The role of endothelin receptor antagonists in IgA nephropathy.\",\"authors\":\"Mitchell Hunter-Dickson, Muh Geot Wong\",\"doi\":\"10.1111/nep.14364\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"There is growing evidence of endothelin receptor antagonists (ERAs) in renoprotection in proteinuric kidney disease including IgA nephropathy (IgAN). Here, we review current evidence, including the use of sparsentan, atrasentan and zibotentan in IgAN. Recent trails of combination therapy including SGLT2 inhibitors and ERAs suggest possible benefit in further reduction of proteinuria and reducing ERA fluid-retention side effects although more evidence is needed for clinical applications.\",\"PeriodicalId\":19264,\"journal\":{\"name\":\"Nephrology\",\"volume\":\"29 Suppl 2 \",\"pages\":\"30-33\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nephrology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/nep.14364\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/nep.14364","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

越来越多的证据表明，内皮素受体拮抗剂（ERAs）在蛋白尿性肾病（包括 IgA 肾病（IgAN））中具有肾保护作用。在此，我们回顾了目前的证据，包括在 IgAN 中使用 sparsentan、astrasentan 和 zibotentan 的情况。最近对包括 SGLT2 抑制剂和 ERA 在内的联合疗法进行的试验表明，联合疗法可能有利于进一步减少蛋白尿和降低 ERA 的液体滞留副作用，但临床应用还需要更多的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The role of endothelin receptor antagonists in IgA nephropathy.

There is growing evidence of endothelin receptor antagonists (ERAs) in renoprotection in proteinuric kidney disease including IgA nephropathy (IgAN). Here, we review current evidence, including the use of sparsentan, atrasentan and zibotentan in IgAN. Recent trails of combination therapy including SGLT2 inhibitors and ERAs suggest possible benefit in further reduction of proteinuria and reducing ERA fluid-retention side effects although more evidence is needed for clinical applications.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nephrology 医学-泌尿学与肾脏学

CiteScore

4.50

自引率

4.00%

发文量

128

审稿时长

4-8 weeks

期刊介绍： Nephrology is published eight times per year by the Asian Pacific Society of Nephrology. It has a special emphasis on the needs of Clinical Nephrologists and those in developing countries. The journal publishes reviews and papers of international interest describing original research concerned with clinical and experimental aspects of nephrology.